Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELYTACT Injection Use-Results Comparison Survey
jRCT2033210469Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2021
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Open-label trial of oncolytic herpes simplex virus type 1 in malignant glioma (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Overall survival. Started Nov 2021; status: recruiting.
02
Drugs
oncolytic herpes simplex virus type 1
03
Conditions
malignant glioma
Beyond the preview
Go deeper on jRCT2033210469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033210469.